Q4 2025 Management View CEO Punit Dhillon outlined recent progress for nimacimab, highlighting the transition from promising early signals to a robust development case. Dhillon stated, "CBeyond ...

A new study published in the journal of BMC Nephrology showed that subcutaneous and intravenous epoetin showed similar ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...

The 12-16-week open-label study evaluated Ruxoprubart as monotherapy in treatment-naïve PNH patients. Key findings include: -- Hemoglobin (Hb) Improvement: Hemoglobin levels increased by 1.5--2.7 g/dL ...

Treatment with SC vs IV tocilizumab led to higher long-term remission rates in GCA-associated aortitis, though imaging and glucocorticoid-sparing outcomes were similar.

Exl-111 is an investigational allergic Effector Cell Response Inhibitor (ECRI) targeting the IgE axis and is designed to disarm allergic ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...

New specialty pharmacy and infusion suite combines compassionate nursing and infusion expertise for patients managing ...

WVU Cancer Institute became the first in the world to treat ultra-rare, aggressive CD19-positive MPAL with subcutaneous blinatumomab in a Phase II trial.